Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer
NCT00422773
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
21
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG:
Cetuximab
Sponsor
Technische Universität Dresden